Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Shiao-Pei WeathersMarta Penas-PradoBe-Lian PeiXiaoyang LingCynthia KassabPinaki BanerjeeMustafa BdiwiHila ShaimAbdullah AlsulimanMayra ShanleyJohn F de GrootBarbara J O'BrienRebecca HarrisonNazanin MajdCarlos Kamiya-MatsuokaGregory N FullerJason T HuseLinda ChiGanesh RaoJeffrey S WeinbergFrederick F LangRaymond SawayaElizabeth J ShpallKatayoun RezvaniAmy B HeimbergerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Adoptive infusion of CMV-specific T cells after lymphodepletion with dose-dense temozolomide was well tolerated. But apparently CMV seropositivity does not guarantee tumor susceptibility to CMV-specific T cells, suggesting heterogeneity in CMV antigen expression. Moreover, effector function of these T cells was attenuated, indicating a requirement for further T-cell modulation to prevent their dysfunction before conducting large-scale clinical studies.